Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,

#3520 Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial

Introduction: TGR has been investigated as a potential biomarker for antitumor drug activity in NETs.

Conference:

Presenting Author:

Authors: Dromain C, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Tumor Growth Rate, Lanreotide Autogel, midgut, pancreatic,

#3219 Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results

Introduction: Increasing LAN dose frequency may extend progression-free survival (PFS).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Pavel M

Authors: Pavel M, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Lanreotide, neuroendocrine tumor, pancreatic, midgut, quality of life,

#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)

Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C,

Keywords: alkylating agents, pancreatic NET, re-challenge, chemotherapy,

#3002 Quality of Life, Tumour Heterogeneity and Biomarker Levels in Patients with Progressive Pancreatic or Midgut Neuroendocrine Tumours: Baseline Data from CLARINET FORTE

Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,

Keywords: Neuroendocrine tumours, lanreotide,